Natural Capsules Fair Value
Natural Capsules (NATCAPSUQ) average fair value is ₹305.53 across 4 valuation models — P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF), vs a current market price of ₹201.37 (+51.73%), fair value range ₹58.74–₹687.38. For live price and a broader fundamental view, visit Natural Capsules screener.
Fair Value Analysis Export
NATCAPSUQ Fair Value vs Current Price — Valuation Summary
NATCAPSUQ average fair value, fair value range, price gap and valuation status across 4 models: P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF). Browse Natural Capsules financial data for revenue, profit, balance sheet and cash flow data.
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Discounted Cash Flow (DCF)
NATCAPSUQ Fair Value Analysis — Data Sources & Coverage
Natural Capsules financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. Read NATCAPSUQ dividend yield for the complete payout history and dividend yield track record.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
NATCAPSUQ vs Healthcare Sector Peers — P/E, P/B & Market Cap
Natural Capsules P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Aurobindo Pharma | AUROPHARMA | 25.88 | 2.53 | ₹96,652 |
| Sat Kartar Life | SATKARTAR | 13.37 | 3.34 | ₹226 |
| Divis Laboratories | DIVISLAB | 85.36 | 14.9 | ₹247,470 |
| Syngene International | SYNGENE | 69.95 | 3.2 | ₹15,307 |
| Emcure Pharmaceuticals | EMCURE | 36.8 | 7.52 | ₹37,799 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.